Naznin Dixit
Pediatric Endocrinology · Jackson, MSNPI 1972515930
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.8%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Ascendis Pharma Endocrinology Inc at 33.2% of the total. Reporting peaked in 2022 at $2,445 and has fallen 63.1% since, to $902 in 2025.
Across 130 payments — averaging $51.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$2K
- Vistapharm, Inc.$2K
- AbbVie$499
- Novo Nordisk$461
- Tolmar, Inc.$180
- Dexcom, Inc.$155
- plus $2K from 26 others
Across 826 payments — averaging $462.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$164K
- Boehringer Ingelheim Pharma GmbH & Co.kg$72K
- Novo Nordisk AS$69K
- Ascendis Pharma Endocrinology Inc$30K
- Eli Lilly$23K
- Astrazeneca UK Limited$14K
- plus $9K from 3 others
What the payments were for
- Consulting fees$1,54023%
- Speaking & faculty fees$2,03431%
- Food & beverage$2,98445%
- Education$1092%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 10 | $2,211 |
| Vistapharm, Inc. | 1 | $1,540 |
| AbbVie | 17 | $499 |
| Novo Nordisk | 17 | $461 |
| Tolmar, Inc. | 6 | $180 |
| Dexcom, Inc. | 7 | $155 |
| Pfizer | 7 | $121 |
| Medtronic | 2 | $116 |
| Abbott | 5 | $110 |
| Azurity Pharmaceuticals, Inc. | 5 | $109 |
| Kyowa Kirin, Inc. | 5 | $105 |
| Tolmar Pharmaceuticals, Inc. | 4 | $83 |
| Tandem Diabetes Care, Inc. | 3 | $81 |
| Eton Pharmaceuticals, Inc. | 2 | $81 |
| Ultragenyx Pharmaceutical Inc. | 4 | $79 |
| Biomarin Pharmaceutical Inc. | 3 | $77 |
| Rhythm Pharmaceuticals, Inc. | 4 | $76 |
| BETA Bionics, Inc. | 3 | $75 |
| Neurocrine Biosciences, Inc. | 3 | $68 |
| Insulet Corporation | 3 | $65 |
| Lilly USA, LLC | 4 | $54 |
| Sanofi-aventis U.S. LLC | 2 | $53 |
| Soleno Therapeutics, Inc. | 2 | $50 |
| AstraZeneca | 2 | $35 |
| Sobi, Inc | 1 | $34 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| IBSA Pharma Inc. | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Lifescan, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SKYTROFA$2,034
- Thyquidity$1,540
- Lupron Depot$124
How this compares
Too few pediatric endocrinology providers in Mississippito place this figure against a meaningful peer group, so we don't.
Other pediatric endocrinology in Jackson
- Anju SukumaranJackson$2K
- Simeen PashaJackson$2K
- Namrata KotwalJackson$945
- Obiageli ObiJackson$679
- George MollJackson$35
- Jessica LilleyTupelo$18K
- Sara SilverTupelo$1K
- Amy PotterMadison$835
- Saima HanifMadison$46
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.